Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Response rates to PD-1 blockade are lower than in colorectal cancer and the reasons are not settled.
Whether checkpoint inhibitors should replace chemotherapy first line is untested in the pancreas.
Immunohistochemistry misses some deficient tumours and over-calls others; confirmatory sequencing is not universal.
Lynch syndrome carriers have no proven pancreatic surveillance strategy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
PFS 16.
A milestone in how this cancer is treated.
OS 54.
A milestone in how this cancer is treated.